Patent · US Active

PEGylated Recombinant Human Growth Hormone Compounds

US10098930B2 · kind B2 · utility

7Cited by
5References
12Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJan 19, 2016
Grant dateOct 16, 2018
Priority date
Expiry dateJan 19, 2036

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K14/61
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

A chemically modified human Growth Hormone (rhGH) prepared by attaching a transient linker which comprises a polyethylene glycol. The chemically modified protein may have a much longer lasting rhGH activity than that of the unmodified rhGH, enabling reduced dose and scheduling opportunities and the modified rhGH may not cause lipoatrophy. Also includes methods of use for the treatment and/or prevention of diseases or disorders in which use of growth hormone is beneficial.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.